Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - The Allergy Therapeutics Plc

11 Apr 2023 10:10

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

River and Mercantile Asset Management PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

The Allergy Therapeutics PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10/04/2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

0.1P ORDINARY

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

28,700,000

4.2262%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

28,700,000

4.2262%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

11 April 2023

Contact name:

Operational Compliance Department

River and Mercantile

RaelaTomas

Telephone number*:

+44 20 3327 5653

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005562/en/

Copyright Business Wire 2023

Date   Source Headline
30th Aug 201211:14 amRNSNotice of results and shareholder update
3rd Aug 20127:00 amRNSFDA Clinical Hold Lifted
31st May 20122:34 pmRNSHolding(s) in Company
23rd May 201211:23 amRNSVoluntary recall of Anapen by Lincoln Medical
17th May 20124:51 pmRNSHolding(s) in Company
17th May 20124:51 pmRNSHolding(s) in Company
16th May 201211:11 amRNSTotal Voting Rights
2nd May 20123:33 pmRNSBoard Appointment
24th Apr 201212:31 pmRNSHolding(s) in Company
20th Apr 20128:01 amRNSConcert Party Shareholding
20th Apr 20128:01 amRNSDirector/PDMR Shareholding
19th Apr 20123:05 pmRNSResult of AGM
18th Apr 20127:00 amRNSResult of Offer
30th Mar 20127:02 amRNSGrant of Options
30th Mar 20127:01 amRNSFundraising Announcement
30th Mar 20127:00 amRNSHalf Yearly Report
14th Mar 20129:23 amRNSNotice of results and shareholder update
21st Feb 20126:12 pmRNSHolding(s) in Company
21st Feb 20126:11 pmRNSHolding(s) in Company
6th Dec 20117:00 amRNSAnapen® 500mcg epinephrine auto-injector
28th Nov 20117:00 amRNSRegulatory update PEI FDA
16th Nov 20115:20 pmRNSAGM Statement
20th Oct 20116:24 pmRNSAnnual Financial Report
29th Sep 201112:45 pmRNSProvisional Grant of Options
19th Sep 20117:00 amRNSFinal Results
19th Sep 20117:00 amRNSDistribution Agreement
8th Sep 20115:06 pmRNSHolding(s) in Company
7th Sep 20117:00 amRNSNotice of Results
23rd Aug 20119:35 amRNSForm 8.3 - [Allergy Therapeutics]
23rd Aug 20117:00 amRNSAllergy Therapeutics enters Latin America
22nd Aug 201112:03 pmRNSForm 8.3 - [Allergy Therapeutics Plc]
8th Jun 20117:00 amRNSRegulatory Update
28th Apr 20117:00 amRNSTotal Voting Rights
26th Apr 20117:00 amRNSFDA Update
20th Apr 20112:59 pmRNSExercise of Options
11th Apr 20114:31 pmRNSHolding(s) in Company
7th Apr 20117:00 amRNSGrass MATA MPL dossier submitted in Switzerland
30th Mar 20116:19 pmRNSDirector/PDMR Shareholding
29th Mar 20113:19 pmRNSDirector/PDMR Shareholding
29th Mar 20113:17 pmRNSDirector/PDMR Shareholding
28th Mar 20117:02 amRNSU.S. regulatory update
28th Mar 20117:00 amRNSHalf Yearly Report
9th Feb 201110:32 amRNSHolding(s) in Company
9th Feb 201110:31 amRNSHolding(s) in Company
1st Dec 20107:00 amRNSTen further MAAs submitted in Germany
18th Nov 201011:52 amRNSResult of AGM
20th Oct 20108:06 amRNSAnnual Financial Report
4th Oct 20109:45 amRNSDirector/PDMR Shareholding
30th Sep 20103:21 pmRNSDirectorate Change
20th Sep 20107:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.